Lanlan Pang

460 total citations
31 papers, 282 citations indexed

About

Lanlan Pang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Lanlan Pang has authored 31 papers receiving a total of 282 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 8 papers in Molecular Biology. Recurrent topics in Lanlan Pang's work include Lung Cancer Treatments and Mutations (12 papers), Colorectal Cancer Treatments and Studies (6 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Lanlan Pang is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Colorectal Cancer Treatments and Studies (6 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Lanlan Pang collaborates with scholars based in China, United Kingdom and United States. Lanlan Pang's co-authors include Chongxiang Chen, Yihua Huang, Jiadi Gan, Wenfeng Fang, Yanyan Wang, Wei Liao, Huan Li, Weitao Zhuang, Jiaojiao Wang and Gang Ma and has published in prestigious journals such as SHILAP Revista de lepidopterología, Cancer and Clinical Cancer Research.

In The Last Decade

Lanlan Pang

28 papers receiving 279 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lanlan Pang China 11 106 97 84 32 31 31 282
Raees Tonse India 10 115 1.1× 95 1.0× 58 0.7× 18 0.6× 31 1.0× 39 292
Luis Cabezón‐Gutiérrez Spain 10 107 1.0× 148 1.5× 74 0.9× 43 1.3× 56 1.8× 44 337
Fernando Vázquez‐Alonso Spain 11 120 1.1× 64 0.7× 101 1.2× 59 1.8× 93 3.0× 43 382
Aurélie Cabrespine France 10 68 0.6× 95 1.0× 60 0.7× 21 0.7× 15 0.5× 26 310
Juan J. Toro United States 8 103 1.0× 92 0.9× 129 1.5× 24 0.8× 13 0.4× 28 300
Timothy A. Zaki United States 9 65 0.6× 139 1.4× 60 0.7× 28 0.9× 32 1.0× 22 315
Ehsan Zaboli Iran 9 45 0.4× 105 1.1× 60 0.7× 23 0.7× 20 0.6× 48 283
Ebunoluwa Otegbeye United States 9 43 0.4× 128 1.3× 45 0.5× 56 1.8× 24 0.8× 19 334
Caitlin Ryan United States 5 39 0.4× 190 2.0× 66 0.8× 32 1.0× 37 1.2× 9 335
C. McClung United States 11 33 0.3× 58 0.6× 89 1.1× 64 2.0× 35 1.1× 25 270

Countries citing papers authored by Lanlan Pang

Since Specialization
Citations

This map shows the geographic impact of Lanlan Pang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lanlan Pang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lanlan Pang more than expected).

Fields of papers citing papers by Lanlan Pang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lanlan Pang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lanlan Pang. The network helps show where Lanlan Pang may publish in the future.

Co-authorship network of co-authors of Lanlan Pang

This figure shows the co-authorship network connecting the top 25 collaborators of Lanlan Pang. A scholar is included among the top collaborators of Lanlan Pang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lanlan Pang. Lanlan Pang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Chen, Maojian, Wei Jiang, Shaoping Zhang, et al.. (2025). Activating NEDD4L suppresses EGFR-driven lung adenocarcinoma growth via facilitating EGFR proteasomal degradation. Journal of Experimental & Clinical Cancer Research. 44(1). 294–294.
3.
Chen, Feifei, Lulu Zhao, Lanlan Pang, et al.. (2025). Wearable physiological monitoring of physical exercise and mental health: A systematic review. Research Portal (King's College London). 1(1). 11–21. 1 indexed citations
4.
Zhuang, Weitao, Dongfang Wu, Lanlan Pang, et al.. (2024). EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47. Journal of Thoracic Oncology. 19(8). 1186–1200. 23 indexed citations
5.
Shi, Mengting, Lanlan Pang, Huaqiang Zhou, et al.. (2024). Rare SMARCA4-deficient thoracic tumor: Insights into molecular characterization and optimal therapeutics methods. Lung Cancer. 192. 107818–107818. 7 indexed citations
6.
Pang, Lanlan, Weitao Zhuang, Junjun Li, et al.. (2024). Specifying the choice of EGFR-TKI based on brain metastatic status for advanced NSCLC with EGFR p.L861Q mutation. Neoplasia. 58. 101073–101073. 1 indexed citations
7.
Pang, Lanlan, Yihua Huang, Weitao Zhuang, et al.. (2024). Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC. Clinical Cancer Research. 30(12). 2636–2646. 5 indexed citations
8.
Pang, Lanlan, Hongning Zhou, Yong Zhang, et al.. (2024). SWI/SNF family mutations in advanced NSCLC: genetic characteristics and immune checkpoint inhibitors’ therapeutic implication. ESMO Open. 9(6). 103472–103472. 3 indexed citations
9.
Pang, Lanlan, Min Shi, Huaqiang Zhou, et al.. (2023). MA08.09 SMARCA4 deficient Thoracic Tumors: Clinicopathological, Molecular Characteristics and Optimal Therapeutics Methods. Journal of Thoracic Oncology. 18(11). S127–S128.
10.
Huang, Yihua, C. Xu, Wenxian Wang, et al.. (2022). Rare EGFR E709-T710delinsX: Molecular characteristics and superior response to afatinib treatment in NSCLC patients. Lung Cancer. 172. 117–123. 1 indexed citations
11.
12.
Gan, Jiadi, et al.. (2021). HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy. OncoTargets and Therapy. Volume 14. 5297–5307. 12 indexed citations
13.
Pang, Lanlan, Xiaoqing Lin, Xuehua Li, et al.. (2021). Role of Telemedicine in Inflammatory Bowel Disease: Systematic Review and Meta-analysis of Randomized Controlled Trials. Journal of Medical Internet Research. 24(3). e28978–e28978. 36 indexed citations
14.
Chen, Chongxiang, Jiaojiao Wang, Lanlan Pang, et al.. (2020). Telemonitor care helps CPAP compliance in patients with obstructive sleep apnea: a systemic review and meta-analysis of randomized controlled trials. Therapeutic Advances in Chronic Disease. 11. 1754193401–1754193401. 28 indexed citations
15.
Chen, Chongxiang, et al.. (2020). Analysis of the Expression of Cell Division Cycle-Associated Genes and Its Prognostic Significance in Human Lung Carcinoma: A Review of the Literature Databases. BioMed Research International. 2020(1). 6412593–6412593. 21 indexed citations
16.
Pang, Lanlan, et al.. (2020). The effects of telemedicine on the quality of life of patients with lung cancer: a systematic review and meta-analysis. Therapeutic Advances in Chronic Disease. 11. 1754253373–1754253373. 25 indexed citations
17.
Chen, Chongxiang, et al.. (2020). The role of the CDCA gene family in ovarian cancer. Annals of Translational Medicine. 8(5). 190–190. 38 indexed citations
18.
X, Li, Lanlan Pang, Zhijun Yang, et al.. (2019). LncRNA HOTAIRM1/HOXA1 Axis Promotes Cell Proliferation, Migration And Invasion In Endometrial Cancer. SHILAP Revista de lepidopterología. 1 indexed citations
19.
Chen, Chongxiang, et al.. (2019). Combination era, using combined vasopressors showed benefits in treating septic shock patients: a network meta-analysis of randomized controlled trials. Annals of Translational Medicine. 7(20). 535–535. 8 indexed citations
20.
Vickers, Andrew J., Robbert van Haselen, Lanlan Pang, & Saul Berkovitz. (2000). Inter-rater reliability of symptom repertorisation: a pragmatic empirical study. British Homeopathic journal. 89(4). 189–191. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Raees Tonse Breakdown of academic impact, for papers by Luis Cabezón‐Gutiérrez Breakdown of academic impact, for papers by Fernando Vázquez‐Alonso Breakdown of academic impact, for papers by Aurélie Cabrespine Breakdown of academic impact, for papers by Juan J. Toro Breakdown of academic impact, for papers by Timothy A. Zaki Breakdown of academic impact, for papers by Ehsan Zaboli Breakdown of academic impact, for papers by Ebunoluwa Otegbeye Breakdown of academic impact, for papers by Caitlin Ryan Breakdown of academic impact, for papers by C. McClung
Rankless by CCL
2026